RxDoctor Payments Data

Joshua Stephens, DO

Internal Medicine · Cincinnati, OHNPI 1427336841

Payments from drug & device makers

$7,111in general payments, 2019–2025

Across 399 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$903
  • AstraZeneca$691
  • Lilly USA, LLC$444
  • Novo Nordisk$334
  • Boehringer Ingelheim$287
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$7,111100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,111 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$33,995
Medicare patients
115
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$43,810
EliquisApixaban25$25,276
MounjaroTirzepatide19$21,984
LinzessLinaclotide14$17,176
JardianceEmpagliflozin14$16,654
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,933
TravasolParenteral Amino Acid 10% No.617$4,452
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$2,834
Atorvastatin Calcium104$952
Gabapentin56$895
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$829
SynthroidLevothyroxine Sodium11$808
Albuterol Sulfate HfaAlbuterol Sulfate19$765
Pregabalin15$655
Venlafaxine Hcl ErVenlafaxine Hcl110$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$334$43,81045 claims
PfizerEliquis$903$25,27625 claims
Lilly USA, LLCMounjaro$444$21,98419 claims
AbbVieLinzess, Synthroid$2,133$17,98425 claims
Boehringer IngelheimJardiance$287$16,65414 claims
AstraZenecaBreztri Aerosphere$691$12,93320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →